Moshkevich Solomon sold $5.9M of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 18,160 shares of Natera, Inc. (NTRA) at an average of $325.88 ($319.76–$326.89, $5.92M total) across 4 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Sep 4, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

Insider sales are monitored for signals of management confidence; a $5.9M sale by the president is noteworthy but not decisive.

02

Market read

The filing provides fresh data on insider activity, offering a modest trading cue for NTRA.

03

What to watch

Potential tax planning or diversification; the insider retains a sizable stake.

Relevance 5/10Novelty 7/10Timing: post‑filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President of Natera sold 18,160 shares for $5.9M via a 10b5‑1 plan.

Expected impact

Potential modest dip of 1‑2% in the next trading session.

Evidence & confidence

A $5.9M sale by a senior officer is material but not large enough to trigger a sharp move.

Market effects

Limited; may slightly affect biotech sentiment but no broader sector impact.

U.S. biotech investors may adjust positions.

Low; isolated to Natera.

Counterpoint

The sale could be routine under a pre‑arranged plan, not a bearish signal.

Key entities

  • Natera, Inc.

    US‑listed prenatal testing company (ticker NTRA).

  • Moshkevich Solomon

    President, Clinical Diagnostics at Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.